Gilead Sciences | GILD - Bruttoergebnis Vom Umsatz

Aktienkurs
138.67
Täglich Wechseln
2.30 1.69%
Monatlich
-7.57%
Jährlich
23.76%
Q1 Prognose
130.22




Bruttoergebnis Vom Umsatz Veränderung Datum
AbbVie USD 10.47B 605M 2025-09
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
ALKERMES USD 338.34M 72.51M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.39B 118.68M 2025-12
J&J USD 16.6B 118M 2025-12
Merck USD 13.42B 431M 2025-09
Moderna USD 226M 583M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.25B 570M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12